BRUPHARM PHARMALAB

Active

Private limited companyfounded 20224 yrs activeRoute de Wallonie (G.) 140, 7011 Mons, BelgiumKBO/BCE: BE 0785.641.404

The computed 12-month bankruptcy probability of BRUPHARM PHARMALAB is 3.2% (moderate). The 2024 annual accounts show negative equity (€-113k) and a net result of €-45k. Equity is shrinking by ~116.4% per year across the filed fiscal years. Its solvency ranks better than 13% of 15868 sector peers (fiscal year 2024). The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.

Watch Print / PDF

Checked score

Score 2024

16 / 100

Critical

The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.

Axes · tick = 2023

Profitability0=

Solvency0▼-3

Growth41▲+19

Track record94

Bankruptcy probability, 12 months

3.2% Moderate

0%0.5%1.5%4%10%≥ 25%

No credit on open account

Liquidity short (current ratio 0.12 against 0.18 in 2023; short-term debt: 146.3% and cash: 0% of total assets), and equity is negative.

How do we compute the score and the probability?

Credit advice for your own amount and term

Signals

Seven signals. The signal on the left, the evidence on the right.

+raises risk○neutral

Limited track record

This company has not been active as long as an established one and statistically fails somewhat more often.

KBO · incorporation date

Age against the risk zone

Annual accounts: weaker financial profile

The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.

NBB · annual accounts 2024

Solvency, return and age of the figures

Solvency

-46.3%

Return on assets

-18.5%

Age of the figures

21 mo

Higher-failure-rate sector

In this sector companies fail more often than the Belgian average.

Gazette · bankruptcies per sector, NACE 46

Relative position

BE, all sectors

reference

Sector 46

higher

← fewer bankruptcies more bankruptcies →

Higher-failure-rate region

In this region companies fail more often than in the rest of the country.

KBO · registered office

Negative equity

The 2024 annual accounts show negative equity and a net loss.

NBB · annual accounts 2024

Equity per financial year

222324

2022 to 2024 · latest year €-113k

Filed more than 90 days late

The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 07-11-2025, 99 days past the deadline. Measured on financial year 2023: companies more than 90 days late are in an abnormal legal state today in 5.61% of cases, against 1.66% across all filers.

NBB · 3 filings

Deviation from the deadline

2025

not confirmed

2024

99 d late

2023

464 d late

2022

262 d late

← before the deadline after the deadline →

No strike-offs in the KBO publications

We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

KBO publications · our coverage

Financials · fiscal year 2024, micro schema

Turnover

€50k▲ 7.0%

2023 · €47k

2022: €59k 2023: €47k

2022 → 2024

EBIT margin

-89.2%▲ 150.1pp

2023 · -239.4%

2022: -93.5% 2023: -239.4%

2022 → 2024

Net result

€-45k▲ 60.0%

2023 · €-113k

2022: €-55k 2023: €-113k

2022 → 2024

Working capital

€-315k▼ 2.4%

2023 · €-308k

2022: €-233k 2023: €-308k

2022 → 2024

Multi-year overview

Every figure with its change against the year before

▲ rise ▼ fall

Line202220232024Trend

Turnover€59k-€47k▼ 20.5%€50k▲ 7.0%

Equity€45k-€-68k€-113k▼ 66.5%

Operating result€-55k-€-112k▼ 104%€-45k▲ 60.1%

Net result€-55k-€-113k▼ 105%€-45k▲ 60.0%

Turnover and EBIT margin not published: the micro schema does not require them.

Result per fiscal year

Operating resultNet result

The operating result stays negative: a loss of €45k in 2024 against €112k in 2023; the loss shrinks.

Balance-sheet composition

2024 in colour, 2023 as the grey bar beneath

Assets €244k

82.9%

17.1%

Fixed assets €202k▼ 15.8%

Current assets €42k▼ 39.4%

Key figures and ratios

2024 value · change against 2023

EBITDA

€-7k▲

2023 · €-74k

Cash flow

€-7k▲

2023 · €-75k

Solvency

-46.3%▼

2023 · -22.0%

Current ratio

0.12▼

2023 · 0.18

Quick ratio

0.10▼

2023 · 0.16

Debt / equity

-3.16▲

2023 · -5.55

ROA

-18.5%▲

2023 · -36.5%

Interest coverage

-12.67▲

2023 · -71.96

Debt

€357k▼

2023 · €377k

Debt ≤ 1 year

€357k▼

2023 · €377k

Staff costs

€9k▼

2023 · €34k

Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.

Filed annual accounts

As filed with the NBB · 2024 against 2023

Balance sheet Code20232024

Assets

Total assets20/58€309k€244k▼

Fixed assets21/28€240k€202k▼

Intangible fixed assets21€239k€202k▼

Tangible fixed assets22/27€627€278▼

Plant, machinery and equipment23€430€149▼

Furniture and vehicles24€197€129▼

Current assets29/58€69k€42k▼

Stocks and contracts in progress3€8k€6k▼

Stocks30/36€8k€6k▼

Amounts receivable within one year40/41€58k€35k▼

Trade receivables40€56k€35k▼

Other amounts receivable41€3k-

Cash at bank and in hand54/58€2k€77▼

Equity and liabilities

Total equity and liabilities10/49€309k€244k▼

Equity10/15€-68k€-113k▼

Contributions10/11€100k€100k=

Capital10€100k€100k=

Issued capital100€100k€100k=

Profit (loss) carried forward14€-168k€-213k▼

Amounts payable17/49€377k€357k▼

Amounts payable within one year42/48€377k€357k▼

Trade debts44€39k€25k▼

Suppliers440/4€39k€25k▼

Taxes, remuneration and social security45€31k€18k▼

Taxes450/3€2k-

Remuneration and social security454/9€30k€18k▼

Other amounts payable47/48€307k€313k▲

Income statement Code20232024

Turnover70€47k€50k▲

Goods, raw materials, services and sundry goods60/61€86k€50k▼

Remuneration, social security and pensions62€34k€9k▼

Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€38k€38k=

Other operating charges640/8-€850

Gross operating margin9900€-40k€3k▲

Operating profit (loss)9901€-112k€-45k▲

Financial charges65/66B€1k€530▼

Recurring financial charges65€1k€530▼

Profit (loss) for the period before taxes9903€-113k€-45k▲

Profit (loss) for the period9904€-113k€-45k▲

Profit (loss) for the period to be appropriated9905€-113k€-45k▲

Appropriation of the result

Profit (loss) to be appropriated9906€-168k€-213k▼

Profit (loss) brought forward from the previous period14P€-55k€-168k▼

The notes to these accounts (6 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

All 4Financial 1Filings 3

2025

07-11

NBB filing Annual accounts filed

fiscal year 2024 · micro schema · 99 days late

07-11

NBB filing Annual accounts filed

fiscal year 2023 · micro schema · 464 days late

2024

18-04

NBB filing Annual accounts filed

fiscal year 2022 · micro schema · 262 days late

2023

31-12

Financial Weakest financial yearnet €-113k

Net result drops to €-113k, the lowest in the series; recovery starts the following year.

Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

Directors · office · real estate

Directors

1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.

Location & real-estate footprint

Registered office, Mons · 1 establishment unit since 2022

establishment The establishment unit on the map

Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Route de Wallonie (G.) 1407011 Mons

Ground area

2.3 ha

Building footprint

5,751 m²

Volume, LiDAR

37,448 m³

Parcel 53030G0552/00C000, Wallonia · tallest building 8.6 m, ±2 floors. Linked by address, not a title deed.

1 establishment unit

BRUPHARM-PHARMALAB

Route de Wallonie (G.) 140, 7011 MonsManufacture of food products

since 20222.334.563.039

1 parcel

Wallonia 1 (100%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
53030G0552/00C000	Wallonia	2.3 ha	1 · 5,751 m²	8.6 m · 2 fl.

Linked by address, not proof of ownership

Methodology

via registered seat: 1

1 of 1 parcel with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Recognitions · licences · registrations

Food safety, FASFC

1 site

Mons2.334.563.039

2 permissions

Toelating · Groothandelaar levensmiddelen · since 18-10-2022

Toelating · Fabrikant voedingssupplementen · since 31-08-2022

Similar companies · same sector, comparable size

Of 1,898 companies in sector 46460 we hold annual accounts for 1,116. 457 are within a factor 10 of this equity.See the whole sector

Company data · Crossroads Bank

Identification

Legal formPrivate limited company

Founded03-05-2022

Fiscal year end31-12

Activities, NACEBEL

21201Manufacture of basic pharmaceutical products and pharmaceutical preparations

46460Wholesale of pharmaceutical and medical goods

10890Manufacture of food products

46389Wholesale of other food products

Sources

Crossroads Bank for EnterprisesNational Bank · 3 filingsAddress and cadastre registers

Data from official sources, last processed on 20-09-2026. Scores and ratios are computed by Checked and are not a credit decision.

Contact details

2 entries

E-mail:evdc@brupharm.net

Establishment Mons 2.334.563.039

Phone:+32(0)65680120

Establishment Mons 2.334.563.039